Olaparib companion diagnostic - Myriad Genetics

Drug Profile

Olaparib companion diagnostic - Myriad Genetics

Alternative Names: BRACAnalysis (Olaparib); BRACAnalysis CDx (Olaparib); Olaparib - BRACAnalysis; Olaparib - BRACAnalysis CDx

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Myriad Genetics
  • Developer AstraZeneca; Myriad Genetics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Ovarian cancer
  • Phase III Pancreatic cancer
  • Clinical Phase Unknown Fallopian tube cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 07 Feb 2017 Myriad Genetics and AstraZeneca agree to conduct tumour BRACAnalysis in six Latin American countries
  • 07 Nov 2016 Myriad Genetics announces intention to make regulatory submission for olaparib companion diagnostic to Japan’s Pharmaceuticals and Medical Devices Agency
  • 07 Oct 2016 Pharmacodynamics data from a clinical trial in Ovarian cancer released by Myriad Genetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top